Spero Therapeutics, LLC
Spero Therapeutics, LLC is listed today as Spero Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2022 | $9 M | Private placement after listing | $2 to $10 million | equity | SEC | |
| Jun 2021 | $40 M | Private placement after listing | $10 to $50 million | equity | SEC | |
| Mar 2017 | $43 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Spero Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: Collaboration revenue - related party $47.03 million (70%), Collaboration revenue $12.59 million (19%), Grant Revenue $7.18 million (11%).
Annual report (SEC XBRL) · Dec 2025
Spero Therapeutics, LLC chose not to state its revenue in its newest notice of a funding round (Nov 2022).
SEC Form D · Nov 2022
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2022
Products and services#
No products or services of Spero Therapeutics, LLC are on record.
Investors#
8 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alphabet Inc. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Atlas Venture Associates IX, LLC | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Atlas Venture Associates IX, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Atlas Venture Fund IX, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| GSK PLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| GV 2015 GP, L.L.C. | Other | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| GV 2015, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Invest A/s Lundbeckfond | Person | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 11 investors.
Largest shareholders today
Institutions holding Spero Therapeutics, Inc. shares, as of Sep 30, 2026.
- GSK plc$11 M15.77%
- Pfizer Inc$3 M4.05%
- Vanguard Capital Management LLC$2 M3.49%
- Mackenzie Financial Corp$2 M3.14%
- Renaissance Technologies LLC$2 M2.42%
- Affinity Asset Advisors, LLC$2 M2.23%
- Arrowstreet Capital, Limited Partnership$1 M1.71%
- Verdad Advisers, LP$1 M1.38%
- Raymond James Financial Inc$1 M1.30%
- Citadel Advisors LLC$1 M1.25%
- BlackRock, Inc.$1 M1.02%
- Geode Capital Management, LLC$1 M0.86%
- Vanguard Fiduciary Trust Co$0 M0.49%
- Two Sigma Investments, LP$0 M0.46%
- Morgan Stanley$0 M0.44%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Ankit Mahadevia | Executive officer | Nov 2022 |
| Kamal C. Hamed | Executive officer | Nov 2022 |
| Satyavrat Shukla | Executive officer | Nov 2022 |
| Tamara C. Joseph | Executive officer | Nov 2022 |
| Timothy C. Keutzer | Executive officer | Nov 2022 |
| Cristina E. Larkin | Executive officer | Jul 2021 |
| David E. Melnick | Executive officer | Jul 2021 |
| Satyavrat E. Shukla | Executive officer | Jul 2021 |
| Tamara E. Joseph | Executive officer | Jul 2021 |
| Timothy E. Keutzer | Executive officer | Jul 2021 |
| Stephen Garbacz | Executive officer | Mar 2017 |
| Ankit Mahadevia | Director | Nov 2022 |
| Cynthia C. Smith | Director | Nov 2022 |
| Frank E. Thomas | Director | Nov 2022 |
| John C. Pottage, Jr. | Director | Nov 2022 |
| Kathleen C. Tregoning | Director | Nov 2022 |
| Milind Deshpande | Director | Nov 2022 |
| Patrick E. Vink | Director | Nov 2022 |
| Scott C. Jackson | Director | Nov 2022 |
| Jean-Francois Formela | Director | Jul 2021 |
| Patrick C. Vink | Director | Jul 2021 |
| Scott Jackson | Director | Jul 2021 |
| Casper Breum | Director | Mar 2017 |
| Patrick Vink | Director | Mar 2017 |
| Reza Halse | Director | Mar 2017 |
| Vikas Goyal | Director | Mar 2017 |
Went public since 2017. Its SEC number is that of a company listed on a stock exchange.